 |
56 Diseases |  |
40 Trials |
|
40 Trials |  |
3062 News |  |
| «12...26272829303132333435363738» |
- | Iclusig (ponatinib) / Takeda, Otsuka
Trial suspension, Metastases: Ponatinib Hydrochloride in Treating Patients With Advanced Biliary Cancer With FGFR2 Fusions (clinicaltrials.gov) - Jul 19, 2017
P2, N=30, Suspended, Sponsor: Mayo Clinic
Recruiting --> Suspended
- | Iclusig (ponatinib) / Takeda, Otsuka, Incyte, dasatinib / Generic mfg.
Journal: Poor outcomes associated with +der(22)t(9;22) and -9/9p in patients with Philadelphia chromosome-positive acute lymphoblastic leukemia receiving chemotherapy plus a tyrosine kinase inhibitor. (Pubmed Central) - Jul 19, 2017
By multivariate analysis, this poor-risk ACA group was independently associated with worse RFS (HR 2.03 [95% CI 1.08-3.30], P=0.03) and OS (HR 2.02 [95% CI 1.10-3.71], P=0.02). Patients with Ph+ ALL who have +der(22)t(9;22) and/or -9/9p in the absence of HeH have relatively poor outcomes when treated with chemotherapy plus a TKI.
- | Journal: Preclinical Modeling of KIF5B-RET Fusion Lung Adenocarcinoma. (Pubmed Central) - Jun 18, 2017
Interestingly, the vandetanib-resistant KIF5B-RET(G810A) mutant displayed gain-of-sensitivity (GOS) to ponatinib and lenvatinib...These results indicate that KIF5B-RET-associated lung tumors are addicted to the fusion oncogene and ponatinib is the most effective inhibitor for targeting KIF5B-RET in lung adenocarcinoma. Moreover, this study finds a novel vandetanib-resistant RET(G810A) mutation and identifies lenvatinib and ponatinib as the secondary drugs to overcome this vandetanib resistance mechanism.
- || Iclusig (ponatinib) / Takeda, Otsuka
Trial primary completion date: PACE: Ponatinib for Chronic Myeloid Leukemia (CML) Evaluation and Ph+ Acute Lymphoblastic Leukemia (ALL) (clinicaltrials.gov) - Jun 16, 2017
P2, N=449, Active, not recruiting, Sponsor: Ariad Pharmaceuticals
Moreover, this study finds a novel vandetanib-resistant RET(G810A) mutation and identifies lenvatinib and ponatinib as the secondary drugs to overcome this vandetanib resistance mechanism. Trial primary completion date: Mar 2017 --> Oct 2017
- | Iclusig (ponatinib) / Takeda, Otsuka, Incyte
Journal: Ponatinib versus imatinib for newly diagnosed chronic myeloid leukaemia: an international, randomised, open-label, phase 3 trial. (Pubmed Central) - Jun 15, 2017
P3
The efficacy of ponatinib treatment of newly diagnosed chronic-phase chronic myeloid leukaemia compared with imatinib could not be assessed due to trial termination, but preliminary data suggest there might be benefit, although with more arterial occlusive events than with imatinib at the doses studied. Because the EPIC trial was terminated early, efficacy of ponatinib in this setting remains to be established.
- ||| Iclusig (ponatinib) / Takeda, Otsuka, Incyte
Trial completion, Metastases: Safety Study of AP24534 to Treat Chronic Myelogenous Leukemia (CML) and Other Hematological Malignancies (clinicaltrials.gov) - Jun 4, 2017
P1, N=81, Completed, Sponsor: Ariad Pharmaceuticals
Because the EPIC trial was terminated early, efficacy of ponatinib in this setting remains to be established. Active, not recruiting --> Completed
- Iclusig (ponatinib) / Takeda, Otsuka
Enrollment change, Trial withdrawal: Dose-Escalation Study of Ponatinib, a FLT3 Inhibitor, With and Without Combination of 5-Azacytidine, in Patients With FLT3-Mutated Acute Myeloid Leukemia (AML) (clinicaltrials.gov) - Jun 2, 2017
P1/2, N=0, Withdrawn, Sponsor: M.D. Anderson Cancer Center
Active, not recruiting --> Completed N=132 --> 0 | Not yet recruiting --> Withdrawn
- | Iclusig (ponatinib) / Takeda, Otsuka
New P2 trial, Stroma, Metastases: POETIG Trial - POnatinib After rEsisTance to Imatinib in GIST (clinicaltrials.gov) - May 31, 2017
P2, N=81, Recruiting, Sponsor: Sebastian Bauer
- | Iclusig (ponatinib) / Takeda, Otsuka, Incyte, dasatinib / Generic mfg.
Journal: Hyper-CVAD plus ponatinib versus hyper-CVAD plus dasatinib as frontline therapy for patients with Philadelphia chromosome-positive acute lymphoblastic leukemia: A propensity score analysis. (Pubmed Central) - May 24, 2017
The clinical outcome of patients treated with HCVAD plus ponatinib appears to be superior to that of patients treated with HCVAD plus dasatinib among individuals with Ph+ ALL. Cancer 2016;122:3650-6.
- | Trial primary completion date: Targeted Therapy in Treating Patients With Relapsed or Refractory Acute Lymphoblastic Leukemia or Acute Myelogenous Leukemia (clinicaltrials.gov) - May 22, 2017
P2, N=24, Recruiting, Sponsor: OHSU Knight Cancer Institute
Cancer 2016;122:3650-6. Trial primary completion date: Mar 2017 --> Sep 2017
- ||||| Iclusig (ponatinib) / Takeda, Otsuka, Blincyto (blinatumomab) / Astellas, Amgen
New P2 trial: NCI-2018-01186: Low-Intensity Chemotherapy, Ponatinib and Blinatumomab in Treating Patients with Philadelphia Chromosome-Positive And/or BCR-ABL Positive Acute Lymphoblastic Leukemia (clinicaltrials.gov) - May 10, 2017
P2, N=60, Not yet recruiting, Sponsor: M.D. Anderson Cancer Center
- ||| Iclusig (ponatinib) / Takeda, Otsuka
Biomarker, Trial initiation date: Study of Ponatinib in Patients With Lung Cancer Preselected Using Different Candidate Predictive Biomarkers (clinicaltrials.gov) - May 1, 2017
P2, N=110, Recruiting, Sponsor: University of Colorado, Denver
Trial primary completion date: Mar 2017 --> Sep 2017 Initiation date: Sep 2013 --> May 2014
- || Iclusig (ponatinib) / Takeda, Otsuka, Incyte, Rituxan (rituximab) / Biogen, Zenyaku Kogyo, Roche
Clinical: Combination Chemotherapy and Ponatinib Hydrochloride in Treating Patients With Acute Lymphoblastic Leukemia (clinicaltrials.gov) - Apr 13, 2017
P2, N=100, Recruiting, Sponsor: M.D. Anderson Cancer Center
Initiation date: Sep 2013 --> May 2014 Trial primary completion date: Oct 2018 --> Oct 2019
- | Iclusig (ponatinib) / Takeda, Otsuka, Incyte
Trial primary completion date: Retrospective Evaluation of CML Patients in the National Compassionate Program (clinicaltrials.gov) - Feb 17, 2017
P=N/A, N=80, Recruiting, Sponsor: Gruppo Italiano Malattie EMatologiche dell'Adulto
Trial primary completion date: Oct 2018 --> Oct 2019 Trial primary completion date: Dec 2016 --> Dec 2017
- Iclusig (ponatinib) / Takeda, Otsuka
Enrollment open, Trial primary completion date: PONALFIL: Ponatinib With Chemotherapy for Young Adults Ph Positive Acute Lymphoblastic Leukemia (clinicaltrials.gov) - Dec 9, 2016
P2, N=30, Recruiting, Sponsor: PETHEMA Foundation
Trial primary completion date: Dec 2016 --> Dec 2017 Not yet recruiting --> Recruiting | Trial primary completion date: Jan 2017 --> Jan 2018
- Iclusig (ponatinib) / Takeda, Otsuka, Incyte
New trial: Comparative Evaluation of Results of Allogeneic Hematopoietic Stem Cells Versus Ponatinib in CML Patients Carrying a Mutation T315I (clinicaltrials.gov) - Dec 4, 2016
P=N/A, N=184, Completed, Sponsor: Hospices Civils de Lyon
- || Iclusig (ponatinib) / Takeda, Otsuka
Trial primary completion date: PACE: Ponatinib for Chronic Myeloid Leukemia (CML) Evaluation and Ph+ Acute Lymphoblastic Leukemia (ALL) (clinicaltrials.gov) - Oct 31, 2016
P2, N=449, Active, not recruiting, Sponsor: Ariad Pharmaceuticals
Not yet recruiting --> Recruiting | Trial primary completion date: Jan 2017 --> Jan 2018 Trial primary completion date: May 2016 --> Mar 2017
- Iclusig (ponatinib) / Takeda, Otsuka
Enrollment open, Trial initiation date, Trial primary completion date: Activity and Risk Profile of Ponatinib in Chronic Phase Patients With Chronic Myeloid Leukemia Resistant to Imatinib (clinicaltrials.gov) - Sep 15, 2016
P2, N=78, Recruiting, Sponsor: Gruppo Italiano Malattie EMatologiche dell'Adulto
Trial primary completion date: May 2016 --> Mar 2017 Not yet recruiting --> Recruiting | Initiation date: Dec 2015 --> Aug 2016 | Trial primary completion date: Jun 2018 --> Dec 2018
- Iclusig (ponatinib) / Takeda, Otsuka, Incyte
Enrollment open, Trial initiation date, Trial primary completion date: Retrospective Evaluation of CML Patients in the National Compassionate Program (clinicaltrials.gov) - Aug 17, 2016
P=N/A, N=80, Recruiting, Sponsor: Gruppo Italiano Malattie EMatologiche dell'Adulto
Not yet recruiting --> Recruiting | Initiation date: Dec 2015 --> Aug 2016 | Trial primary completion date: Jun 2018 --> Dec 2018 Not yet recruiting --> Recruiting | Initiation date: Jul 2015 --> Dec 2015 | Trial primary completion date: Jul 2016 --> Dec 2016
- Enrollment change: Targeted Therapy in Treating Patients With Relapsed or Refractory Acute Lymphoblastic Leukemia or Acute Myelogenous Leukemia (clinicaltrials.gov) - Aug 1, 2016
P2, N=24, Recruiting, Sponsor: OHSU Knight Cancer Institute
Not yet recruiting --> Recruiting | Initiation date: Jul 2015 --> Dec 2015 | Trial primary completion date: Jul 2016 --> Dec 2016 N=50 --> 24
- ||||| Iclusig (ponatinib) / Takeda, Otsuka
New P1/2 trial: Dose-Escalation Study of Ponatinib, a FLT3 Inhibitor, With and Without Combination of 5-Azacytidine, in Patients With FLT3-Mutated Acute Myeloid Leukemia (AML) (clinicaltrials.gov) - Jul 12, 2016
P1/2, N=132, Not yet recruiting, Sponsor: M.D. Anderson Cancer Center
- New P1 trial: Personalized Kinase Inhibitor Therapy Combined With Chemotherapy in Treating Patients With Newly Diagnosed Acute Myeloid Leukemia and Acute Lymphoblastic Leukemia (clinicaltrials.gov) - May 20, 2016
P1, N=24, Recruiting, Sponsor: OHSU Knight Cancer Institute
- Iclusig (ponatinib) / Takeda, Otsuka
New P2 trial: PONALFIL: Ponatinib With Chemotherapy for Young Adults Ph Positive Acute Lymphoblastic Leukemia (clinicaltrials.gov) - May 18, 2016
P2, N=30, Not yet recruiting, Sponsor: PETHEMA Foundation
- | Iclusig (ponatinib) / Takeda, Otsuka
Trial termination: Ponatinib - Frontline for Chronic Myeloid Leukemia (CML) in Accelerated Phase (AP) (clinicaltrials.gov) - May 16, 2016
P2, N=51, Terminated, Sponsor: M.D. Anderson Cancer Center
N=50 --> 24 Completed --> Terminated; Closed due to slow accrual
- |||| Iclusig (ponatinib) / Takeda, Otsuka, Incyte, Rituxan (rituximab) / Biogen, Zenyaku Kogyo, Roche
Clinical: Combination Chemotherapy and Ponatinib Hydrochloride in Treating Patients With Acute Lymphoblastic Leukemia (clinicaltrials.gov) - May 16, 2016
P2, N=100, Recruiting, Sponsor: M.D. Anderson Cancer Center
Completed --> Terminated; Closed due to slow accrual Active, not recruiting --> Recruiting
- ||| Iclusig (ponatinib) / Takeda, Otsuka, Incyte, Rituxan (rituximab) / Biogen, Zenyaku Kogyo, Roche
Clinical: Combination Chemotherapy and Ponatinib Hydrochloride in Treating Patients With Acute Lymphoblastic Leukemia (clinicaltrials.gov) - May 13, 2016
P2, N=100, Active, not recruiting, Sponsor: M.D. Anderson Cancer Center
Active, not recruiting --> Recruiting Recruiting --> Active, not recruiting
- |||| Iclusig (ponatinib) / Takeda, Otsuka
Trial completion, Enrollment change, Trial primary completion date: Ponatinib - Frontline for Chronic Myeloid Leukemia (CML) in Accelerated Phase (AP) (clinicaltrials.gov) - May 13, 2016
P2, N=51, Completed, Sponsor: M.D. Anderson Cancer Center
Recruiting --> Active, not recruiting Active, not recruiting --> Completed | N=80 --> 51 | Trial primary completion date: Apr 2017 --> May 2016
- ||| Iclusig (ponatinib) / Takeda, Otsuka, Incyte, Rituxan (rituximab) / Biogen, Zenyaku Kogyo, Roche
Clinical: Combination Chemotherapy and Ponatinib Hydrochloride in Treating Patients With Acute Lymphoblastic Leukemia (clinicaltrials.gov) - Mar 21, 2016
P2, N=100, Recruiting, Sponsor: M.D. Anderson Cancer Center
Active, not recruiting --> Completed | N=80 --> 51 | Trial primary completion date: Apr 2017 --> May 2016 N=60 --> 100 | Trial primary completion date: Oct 2017 --> Oct 2018
- Iclusig (ponatinib) / Takeda, Otsuka
Trial primary completion date: Ponatinib for FLT3-ITD Acute Myelogenous Leukemia (clinicaltrials.gov) - Mar 18, 2016
P1/2, N=40, Recruiting, Sponsor: Central Hospital, Versailles
N=60 --> 100 | Trial primary completion date: Oct 2017 --> Oct 2018 Trial primary completion date: Nov 2015 --> Nov 2016
- Iclusig (ponatinib) / Takeda, Otsuka
Trial primary completion date, Metastases: Ponatinib in Advanced NSCLC w/ RET Translocations (clinicaltrials.gov) - Mar 18, 2016
P2, N=20, Recruiting, Sponsor: Massachusetts General Hospital
Trial primary completion date: Nov 2015 --> Nov 2016 Trial primary completion date: Jun 2015 --> Jun 2018
- Iclusig (ponatinib) / Takeda, Otsuka
Enrollment change, Trial termination, Trial primary completion date, Metastases: Ponatinib for Advanced Medullary Thyroid Cancer (clinicaltrials.gov) - Mar 18, 2016
P2, N=3, Terminated, Sponsor: National Institutes of Health Clinical Center (CC)
N=31 --> 3 | Recruiting --> Terminated | Trial primary completion date: Mar 2016 --> Dec 2015; Recruiting halted prematurely and will not resume. New study to open soon.
- || Iclusig (ponatinib) / Takeda, Otsuka
Trial primary completion date: PACE: Ponatinib for Chronic Myeloid Leukemia (CML) Evaluation and Ph+ Acute Lymphoblastic Leukemia (ALL) (clinicaltrials.gov) - Feb 17, 2016
P2, N=449, Active, not recruiting, Sponsor: Ariad Pharmaceuticals
New study to open soon. Trial primary completion date: Oct 2020 --> May 2016
- || Iclusig (ponatinib) / Takeda, Otsuka, Incyte
Trial primary completion date, Metastases: Safety Study of AP24534 to Treat Chronic Myelogenous Leukemia (CML) and Other Hematological Malignancies (clinicaltrials.gov) - Feb 17, 2016
P1, N=81, Active, not recruiting, Sponsor: Ariad Pharmaceuticals
Trial primary completion date: Oct 2020 --> May 2016 Trial primary completion date: Apr 2017 --> May 2016
- Iclusig (ponatinib) / Takeda, Otsuka
Trial primary completion date, Stroma, Metastases: A Phase 2 Trial of Ponatinib in Participants With Metastatic and/or Unresectable Gastrointestinal Stromal Tumor (clinicaltrials.gov) - Feb 12, 2016
P2, N=45, Active, not recruiting, Sponsor: Ariad Pharmaceuticals
Trial primary completion date: Apr 2017 --> May 2016 Trial primary completion date: Jun 2016 --> Feb 2015
- ||| Iclusig (ponatinib) / Takeda, Otsuka, Incyte
Enrollment open: OMNI: An Observational Registry to Evaluate the Incidence of and Risk Factors for Vascular Occlusive Events Associated With ICLUSIG (clinicaltrials.gov) - Jan 25, 2016
P=N/A, N=300, Recruiting, Sponsor: Ariad Pharmaceuticals
Trial primary completion date: Jun 2016 --> Feb 2015 Not yet recruiting --> Recruiting
- || Iclusig (ponatinib) / Takeda, Otsuka, Incyte, Rituxan (rituximab) / Biogen, Zenyaku Kogyo, Roche
Clinical: Combination Chemotherapy and Ponatinib Hydrochloride in Treating Patients With Acute Lymphoblastic Leukemia (clinicaltrials.gov) - Jan 20, 2016
P2, N=60, Recruiting, Sponsor: M.D. Anderson Cancer Center
Not yet recruiting --> Recruiting Trial primary completion date: Oct 2016 --> Oct 2017
- Iclusig (ponatinib) / Takeda, Otsuka
Enrollment change, Trial withdrawal: Ponatinib in the Treatment of FGFR Mutation Positive Recurrent or Persistent Endometrial Carcinoma (clinicaltrials.gov) - Dec 18, 2015
P=N/A, N=0, Withdrawn, Sponsor: Washington University School of Medicine
Trial primary completion date: Oct 2016 --> Oct 2017 N=15 --> 0 | Not yet recruiting --> Withdrawn
- |||||||||| Iclusig (ponatinib) / Takeda, Otsuka
New P3 trial: OPTIC-2L: A Study Comparing Ponatinib and Nilotinib in Participants With Chronic Myeloid Leukemia (clinicaltrials.gov) - Dec 11, 2015
P3, N=600, Recruiting, Sponsor: Ariad Pharmaceuticals
- Trial primary completion date: Targeted Therapy in Treating Patients With Relapsed or Refractory Acute Lymphoblastic Leukemia or Acute Myelogenous Leukemia (clinicaltrials.gov) - Oct 22, 2015
P2, N=50, Recruiting, Sponsor: OHSU Knight Cancer Institute
N=15 --> 0 | Not yet recruiting --> Withdrawn Trial primary completion date: Jun 2015 --> Mar 2017
- Iclusig (ponatinib) / Takeda, Otsuka
Trial initiation date: Activity and Risk Profile of Ponatinib in Chronic Phase Patients With Chronic Myeloid Leukemia Resistant to Imatinib (clinicaltrials.gov) - Sep 30, 2015
P2, N=78, Not yet recruiting, Sponsor: Gruppo Italiano Malattie EMatologiche dell'Adulto
Trial primary completion date: Jun 2015 --> Mar 2017 Initiation date: Jun 2015 --> Dec 2015
- Iclusig (ponatinib) / Takeda, Otsuka
Trial initiation date, Trial primary completion date: Ponatinib in the Treatment of FGFR Mutation Positive Recurrent or Persistent Endometrial Carcinoma (clinicaltrials.gov) - Sep 21, 2015
P=N/A, N=15, Not yet recruiting, Sponsor: Washington University School of Medicine
Initiation date: Jun 2015 --> Dec 2015 Initiation date: Aug 2015 --> Jan 2016 | Trial primary completion date: Feb 2016 --> Jul 2018
- Iclusig (ponatinib) / Takeda, Otsuka, Avastin (bevacizumab) / Roche
Enrollment open: Trial of Ponatinib in Patients With Bevacizumab-Refractory Glioblastoma (clinicaltrials.gov) - Jul 23, 2015
P2, N=32, Recruiting, Sponsor: Dana-Farber Cancer Institute
Initiation date: Aug 2015 --> Jan 2016 | Trial primary completion date: Feb 2016 --> Jul 2018 Not yet recruiting --> Recruiting
- Iclusig (ponatinib) / Takeda, Otsuka
Enrollment open: OPTIC: Ponatinib in Participants With Resistant Chronic Phase Chronic Myeloid Leukemia (CP-CML) to Characterize the Efficacy and Safety of a Range of Doses (clinicaltrials.gov) - Jul 10, 2015
P2, N=450, Recruiting, Sponsor: Ariad Pharmaceuticals
Not yet recruiting --> Recruiting Not yet recruiting --> Recruiting
- Iclusig (ponatinib) / Takeda, Otsuka, Avastin (bevacizumab) / Roche
New P2 trial: Trial of Ponatinib in Patients With Bevacizumab-Refractory Glioblastoma (clinicaltrials.gov) - Jun 23, 2015
P2, N=32, Not yet recruiting, Sponsor: Dana-Farber Cancer Institute
- ||| Iclusig (ponatinib) / Takeda, Otsuka
Enrollment closed, Trial primary completion date: Ponatinib - Frontline for Chronic Myeloid Leukemia (CML) in Accelerated Phase (AP) (clinicaltrials.gov) - Jun 11, 2015
P2, N=80, Active, not recruiting, Sponsor: M.D. Anderson Cancer Center
Not yet recruiting --> Recruiting Trial primary completion date: Apr 2016 --> Apr 2017 | Recruiting --> Active, not recruiting
- ||||| Iclusig (ponatinib) / Takeda, Otsuka
New P2 trial: OPTIC: Ponatinib in Participants With Resistant Chronic Phase Chronic Myeloid Leukemia (CP-CML) to Characterize the Efficacy and Safety of a Range of Doses (clinicaltrials.gov) - Jun 10, 2015
P2, N=450, Not yet recruiting, Sponsor: Ariad Pharmaceuticals
- ||| Iclusig (ponatinib) / Takeda, Otsuka, Incyte
New trial: OMNI: An Observational Registry to Evaluate the Incidence of and Risk Factors for Vascular Occlusive Events Associated With ICLUSIG (clinicaltrials.gov) - May 27, 2015
P=N/A, N=300, Not yet recruiting, Sponsor: Ariad Pharmaceuticals
- Iclusig (ponatinib) / Takeda, Otsuka, Incyte
New trial: Retrospective Evaluation of CML Patients in the National Compassionate Program (clinicaltrials.gov) - May 19, 2015
P=N/A, N=80, Not yet recruiting, Sponsor: Gruppo Italiano Malattie EMatologiche dell'Adulto
- | Iclusig (ponatinib) / Takeda, Otsuka
New P2 trial: Activity and Risk Profile of Ponatinib in Chronic Phase Patients With Chronic Myeloid Leukemia Resistant to Imatinib (clinicaltrials.gov) - Mar 26, 2015
P2, N=78, Not yet recruiting, Sponsor: Gruppo Italiano Malattie EMatologiche dell'Adulto
- Iclusig (ponatinib) / Takeda, Otsuka
Trial initiation date: Ponatinib in the Treatment of FGFR Mutation Positive Recurrent or Persistent Endometrial Carcinoma (clinicaltrials.gov) - Mar 10, 2015
P=N/A, N=15, Not yet recruiting, Sponsor: Washington University School of Medicine
Trial primary completion date: Apr 2016 --> Apr 2017 | Recruiting --> Active, not recruiting Initiation date: Oct 2014 --> Aug 2015